Related content

Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban

By Giorgi Mariano A   Cohen Arazi Hernáán   Gonzalez Claudio D   Di Girolamo Guillermo  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 567-577

Informa Healthcare

Access to resources Recommend Favorite

Anticoagulation prescription in atrial fibrillation

By Bertomeu-Gonzáález Vicente   Cordero Alberto   Mazóón Pilar   Moreno-Arribas Joséé   Fáácila Lorenzo   Nuññez Julio   Rodrííguez-Maññero Moiséés   Cosíín-Sales Juan   Gonzáález-Juanatey Jose Ramóón   Quiles Juan   Bertomeu-Martíínez Vicente  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1473-1479

Informa Healthcare

Access to resources Recommend Favorite

Antiarrhythmic drugs for atrial fibrillation

By Marinelli Alessandro   Capucci Alessandro  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1201-1215

Informa Healthcare

Access to resources Recommend Favorite

Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice

By Dobrev Dobromir  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1195-1199

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation†

By Garnock-Jones Karly P.  

Drugs & Aging, Vol. 28, Iss. 5, 2011-05 ,pp. : 415-419

Adis International

Access to resources Recommend Favorite